Ovation Science (CSE:OVAT) is Innovating the Way We Use CBD

    Ovation Science Inc. (CSE:OVAT) is an advanced, science-based company ready to capitalize in the cannabis market with their innovative pharmaceutical-grade technology

    Athena Dykman | April 26, 2019 | SmallCapPower: Due to recent legalization trends, the cannabis market has become a massive and rapidly-growing force in the world. With its incredible medicinal and recreational benefits, many companies have entered the market in an attempt to deliver their product in a safe and effective manner that customers will enjoy and trust. Perhaps none have taken this challenge quite to heart like Ovation Science Inc. (CSE:OVAT) and their ground-breaking product portfolio.

    Hear directly from Investor Relations at Ovation Science Inc. (CSE:OVAT)
    Sign up for our FREE daily investment newsletter

    We will never share your data with a third-party without your consent.

    Ovation Science is an advanced, science-based company ready to capitalize in the cannabis market with their innovative pharmaceutical-grade technology. Their newly-launched line of skincare products, ARLO Beauty, is aimed at fighting the signs of aging using hemp-derived cannabidiol (CBD) and their patented Invisicare drug delivery technology. CBD has been shown to act as an anti-inflammatory and antioxidant and it is non-psychoactive – meaning there’s no high from using it. They currently offer an eye cream, day cream, night cream, and a hand and body lotion for an all-over solution. Also in the works is a solid product pipeline of additional skincare offerings poised to launch later this year that will no doubt disrupt the retail and online marketplace.

    Ovation Science is backed by over 20 years of research and development, focusing on transdermal and topical drug delivery systems and it takes its science seriously. That’s why they have formed an exclusive partnership with Skincareguide.com Ltd., to form Ovation’s Medical Dermatology Advisory Board to provide guidance for cannabis-formulated products. Skincareguide.com Ltd. is a leading international peer-reviewed publisher, and highly respected in the industry. As an influential source of dermatological education for both doctors and consumers since 2001, it will aid Ovation Science in the continued production of dermatology-focused CBD products that are both safe and effective in their treatments. The Medical Dermatology Advisory Board is made up of leading physicians from all over the world, who bring with them their immense experience, informed opinions and clinical knowledge.

    “Ovation is a company focused on providing science to support our product lines; that’s what we are all about,” said Doreen McMorran, Chief Operating Officer of Ovation. “Our new Dermatology Advisory Board is an important addition to Ovation’s research and development process and is a great complement to Ovation’s team that combined has over 75 years of dermatology, pharmaceutical and drug delivery experience. Our goal is to provide consumers with products that enhance their health and appearance and ultimately their quality of life and they will experience just that with our ARLO Beauty line of products.”

    Due to recent changes to their licensing agreement, Ovation Science is now able to immediately enter the U.S.  market and offer both dispensary and non-dispensary products in other countries. As CBD products become more acceptable, consumer demand has skyrocketed – and the CBD skincare market is looking to grow to $25 billion worldwide in the next decade, according to research firm Jefferies. As the market opens up and calls for legalization become wider, the need for innovation and outside-the-box thinking is more critical by the moment. That’s why Ovation Science stands out among the rest – they are one step ahead of an already cutting edge industry and are doing it on a global scale, with proven experience and proven results.

    To find out more about Ovation Science Inc. (CSE:OVAT), please visit the company’s Investor Hub.

    Hear directly from Investor Relations at Ovation Science Inc. (CSE:OVAT)
    Sign up for our FREE daily investment newsletter

    We will never share your data with a third-party without your consent.

    Ubika Research/SmallCapPower has received compensation from Ovation Science Inc. to provide analyst research coverage. For full disclosure please visit here >>

    To read our full disclosure, please click on the button below: